Positions

Overview

  • Dr. Falkson joined the Hematology/Oncology Faculty at UAB as a Professor of Medicine and Senior Scientist, Comprehensive Cancer Center in 2001. She is an alumnus of the MD Anderson Cancer Center.
  • Research Overview

  • Carla I. Falkson has been actively involved in development and planning of trials, with an emphasis on clinical trials. Her research has been focused on developing innovative treatments for patients with cancer, as well as coordinating other aspects of cancer research. Her major interests are in the areas of breast cancer and melanoma. She is actively involved in planning ECOG's scientific research program. Examples of research include:

    Breast Cancer – designing adjuvant and metastatic trials, with emphasis on translational research and quality of life issues for women with breast cancer.

    Dr. Falkson is actively involved with development and planning of trials, with an emphasis on clinical trials in breast cancer. She is interested in fostering collaboration between groups and is Principal Investigator for UAB's Eastern Cooperative Oncology Group(ECOG) projects. She has been an active member of the ECOG Breast Committee since 1989 and a member of various other international breast cancer groups (for example BCIRG/CIRC).
    Examples of research include the use of bisphosphonates in breast cancer and chairing studies with these agents such as NSABP-B 34 and S 0307 for ECOG. The use of antiangiogenic agents in breast cancer and treatments for Her2-positive breast cancer are also areas of focus.

    Dr. Falkson has been actively involved with quality assurance in cancer research, including
    chairing UAB's Quality Assurance Committee and ECOG's Audit committee, and has been a
    member of the ECOG Publications Committee and Audit Committee since 1996.

    Other examples of research interests include: Bone metastatases in breast cancer; bisphosphonates as adjuvant therapy for breast cancer; clinical aspects of gamma delta T-cells in breast cancer; circulating serum-Her-2 neu in serum in breast cancer; Herceptin in breast cancer and tumor exosomal jak3BP-mediated immunosuppresion of NK cells in patients with breast cancer. Dr Falkson has also been involved with genetic studies (BRCA determination) in various South African populations. (Done in collaboration with the Department of Human Genetics, University of Pretoria) and co-chaired various breast cancer genetic studies in Pretoria (1995-2001) and co-chairman of various genetic studies eg BRCA1 & 2 determinations (see publications) and been a member of the ECOG Gene Therapy Committee (1997-2001).
  • Education And Training

  • Doctor of Medicine, University of Pretoria 1982
  • Full Name

  • Carla Falkson